Aortic Stenosis

valve implantation (TAVI) (sometimes called transcatheter aortic valve replacement, or TAVR) is a less invasive method of aortic valve replacement. TAVI valves are constructed differently than SAVR valves; TAVI valves are inserted through an artery in a collapsed configuration to the aortic valve site and are then deployed/expanded to replace the stenotic aortic valve. The choice is between the up-front risk and morbidity of SAVR versus the unknown durability of TAVI valves beyond 10 years, although durability studies ranging up to 10 years suggest a structural valve degeneration rate < 10% within that time frame (3, 4, 5). Guidelines to inform shared decision-making suggest SAVR for patients < 65 years; TAVI is preferred for patients whose arteries are suitable for the transfemoral approach and who are > 80 years or who have a life expectancy of < 10 years. In patients aged 65 to 80 years whose arteries are suitable for transfemoral TAVI, the decision regarding SAVR or TAVI is determined based on individual patient characteristics (1). If the patientâ€™s arteries are not suited to the transfemoral route, then SAVR is preferred as long as surgical risk is not prohibitive. In patients with a life expectancy of < 1 year
